Table 1.
Sociodemographic and neuropsychological data of the first-episode of psychosis participants included in the study. They were divided into cannabis non-users (CNU) and cannabis users (CU) groups. N = sample size. Premorbid IQ = Premorbid Intelligence Quotient. TAP = Word Accentuation Test. PANSS = Positive and Negative Symptoms Scale. GAF = Global Assessment of Functioning. CPZ = Chlorpromazine. The mean value (standard deviation) is given for the quantitative variables. For statistical comparisons, the t-student test was used for the quantitative variables and the chi-squared test for the sex variable.
| Cannabis Non-Users (CNU) | Cannabis Users (CU) |
CNU vs. CU Comparison p-Value |
|
|---|---|---|---|
| N | 20 | 20 | - |
| Age (years) | 26.19 (7.72) | 25.94 (5.31) | 0.87 |
| Sex (male/female) | 15/5 | 16/4 | 0.71 |
| Premorbid IQ (TAP a) | 97.24 (11.29) | 98.78 (7.95) | 0.64 |
| PANSS scale | |||
| PANSS positive | 15.90 (5.86) | 18.45 (4.80) | 0.14 |
| PANSS negative | 16.20 (8.46) | 16.95 (8.34) | 0.78 |
| PANSS general | 30.25 (7.60) | 33.85 (8.92) | 0.18 |
| GAF b | 52.11 (11.11) | 48.74 (10.94) | 0.36 |
| CPZ c equivalents (mg/day) | 292.65 (145.16) | 301.20 (181.88) | 0.64 |
a Data of TAP were available for 35 patients. b Data of GAF were available for 37 patients. c All patients except 2 were on antipsychotic treatment when the functional Magnetic Resonance Imaging (fMRI) protocol was performed.